What are the Enzyme Immunoassay (EIA), Rapid Plasma Reagin (RPR), and Treponema pallidum Particle Agglutination (TP-PA) tests for syphilis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Syphilis Serologic Testing: EIA, RPR, and TP-PA

Overview of Test Types

Syphilis diagnosis requires both nontreponemal and treponemal tests used together, as relying on a single test type is insufficient for accurate diagnosis. 1


Enzyme Immunoassay (EIA)

What It Detects

  • EIA is a treponemal test that detects specific antibodies against Treponema pallidum antigens and is commonly used as an automated screening test in modern laboratory algorithms. 2, 3

Key Characteristics

  • Remains reactive for life in most patients (85-100%) regardless of treatment or disease activity, making it unsuitable for monitoring treatment response. 2, 1
  • High sensitivity (96-100%) across all stages of syphilis, including late latent disease where nontreponemal tests may be negative. 4, 3
  • Can be automated for high-throughput screening, which has led many laboratories to adopt "reverse sequence" algorithms starting with EIA. 3

Clinical Interpretation

  • A reactive EIA requires confirmation with a nontreponemal test (RPR) to determine disease activity, and if discordant, a second treponemal test like TP-PA should be performed. 1, 3
  • 15-25% of patients treated during primary syphilis may revert to serologically nonreactive after 2-3 years, but most remain reactive indefinitely. 2, 1

Rapid Plasma Reagin (RPR)

What It Detects

  • RPR is a nontreponemal test that detects antiphospholipid antibodies (not specific to T. pallidum) produced by the host in response to phosphatidylcholine released from damaged cells during infection. 2, 5

Key Characteristics

  • Titers correlate with disease activity and must be reported quantitatively (e.g., 1:16,1:32) to monitor treatment response. 2
  • A fourfold change in titer (two dilutions, e.g., 1:16 to 1:4) indicates clinically significant change in disease activity or treatment response. 2, 1
  • Sensitivity varies by stage: 70-80% in primary syphilis, 97-100% in secondary syphilis, 61-76% in late latent syphilis. 1, 5

Clinical Interpretation

  • RPR becomes nonreactive after successful treatment in most patients, though some maintain low titers indefinitely (serofast reaction). 2
  • Sequential tests must use the same method (RPR or VDRL) by the same laboratory, as RPR titers are typically slightly higher than VDRL and cannot be directly compared. 2
  • False-positive results can occur with HIV infection, pregnancy, autoimmune diseases, hepatitis, and illicit drug use. 2, 5

Critical Pitfall

  • RPR has highest specificity (100%) but lower sensitivity in late-stage disease, so a negative RPR does not exclude syphilis, particularly in late latent or tertiary stages. 1, 6

Treponema pallidum Particle Agglutination (TP-PA)

What It Detects

  • TP-PA is a treponemal test that detects specific antibodies against T. pallidum using gelatin particle agglutination technology. 2, 4

Key Characteristics

  • Among the most sensitive (96.5%) and specific (95.5%) treponemal tests available, making it ideal for confirmatory testing. 7, 4
  • Remains reactive for life in most patients regardless of treatment, similar to other treponemal tests. 1
  • Used as the second treponemal test in reverse algorithm discordant resolution when EIA is reactive but RPR is nonreactive. 4, 3

Clinical Interpretation

  • TP-PA is the gold standard confirmatory treponemal test when there is discordance between initial screening tests. 4
  • Cannot be used to monitor treatment response because titers correlate poorly with disease activity. 2
  • A reactive TP-PA with nonreactive RPR typically indicates late latent syphilis, prior treated syphilis, or rarely a false-positive treponemal test. 1

Practical Testing Algorithm

Traditional Algorithm

  • Screen with RPR first, then confirm reactive results with treponemal test (EIA or TP-PA). 2

Reverse Algorithm (Increasingly Common)

  • Screen with automated treponemal EIA first, then test reactive samples with RPR. 3
  • If EIA reactive but RPR nonreactive, perform TP-PA as second treponemal test to resolve discordance. 1, 3
  • If both EIA and TP-PA are reactive but RPR is nonreactive, treat as late latent syphilis (benzathine penicillin G 2.4 million units IM weekly × 3 weeks). 1

Monitoring Treatment

  • Use RPR titers exclusively to monitor treatment response, repeating at 6,12, and 24 months after treatment. 1, 5
  • A fourfold decline in RPR titer indicates successful treatment. 1, 5

Special Considerations

HIV-Infected Patients

  • Standard serologic tests remain accurate for most HIV-infected patients, though atypical results (unusually high, low, or fluctuating titers) can occur. 2
  • False-positive nontreponemal tests may be more common in HIV-infected persons. 2, 5

Neurosyphilis

  • No single test diagnoses neurosyphilis; diagnosis requires combination of reactive serology, CSF abnormalities (elevated protein, lymphocytic pleocytosis >5 WBC/mm³), and reactive VDRL-CSF. 2, 1
  • RPR cannot be performed on CSF; only VDRL-CSF is validated for cerebrospinal fluid testing. 2

References

Guideline

Syphilis Diagnosis Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Analytical evaluation of nine serological assays for diagnosis of syphilis.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2015

Guideline

Diagnóstico y Manejo de la Sífilis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.